EYE National Vision (EYE) Insider Trading, Ownership & Congress Trades
Medical Devices · Ophthalmic goods · CIK 0001710155
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
131
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed
What the filings say about EYE
Insiders, 180 days
+$776.0K net bought
1 buyer
National Vision insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, National Vision Holdings, Inc. insiders bought a net $776.0K of stock across 38 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 50,000 shares held after it.
- No other insider bought within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Nicholson Michael J bought about $776.0K of EYE on Jun 5, 2026, the largest insider purchase at the company since 2022; 131 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 213.0% of the 16,431 shares held after it.
- 1 other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Wilkes Alexander sold about $928.9K of EYE on Mar 11, 2026; 1 other insider sold within 30 days and 131 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (3 buys, 10 sales), the last on Sep 16, 2025.
- -20.5% median (-7.9% mean) 90-day return after 3 previous buys.
- The trade is 1.1% of the 694,880 shares held after it.
- 1 other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman FAHS L READE sold about $224.8K of EYE on Mar 6, 2026; 1 other insider sold within 30 days and 131 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (3 buys, 10 sales), the last on Sep 16, 2025.
- -20.5% median (-7.9% mean) 90-day return after 3 previous buys.
- The trade is 1.1% of the 359,359 shares held after it.
- 1 other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman FAHS L READE sold about $120.4K of EYE on Mar 6, 2026; 1 other insider sold within 30 days and 131 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (3 buys, 9 sales), the last on Sep 15, 2025.
- -20.5% median (-7.9% mean) 90-day return after 3 previous buys.
- The trade is 2.0% of the 532,195 shares held after it.
- No other insider sold within 30 days.
- 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman FAHS L READE sold about $253.6K of EYE on Sep 16, 2025; 131 funds added in the latest 13F quarter.38 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$776.0K over 180 days
more than 91% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
131 funds bought in last quarter
more than 71% of Medical Devices
Revenue
+9.0% year over year
below 51% of Medical Devices
Margin
1.5% net margin
more than 69% of Medical Devices
Buybacks
$30.6M repurchased, FY to 2026-07-04
below 54% of Medical Devices
Short interest
20.2% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30
more than 99% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EYE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-27.1%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EYE: institutional holders (13F)
13F holdings, latest reported quarter
12,114,392 sh
$230.3M
7,669,853 sh
$145.8M
5,432,564 sh
$103.3M
4,747,422 sh
$90.2M
4,070,392 sh
$77.4M
Congress trades in EYE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EYE planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
EYE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
WPG Partners Select Small Cap Value Fund
$4.3M position · as of 2026-05-31
1.8%
State Street(R) SPDR(R) S&P(R) Retail ETF
$5.6M position · as of 2026-06-30
1.5%
Dunham Small Cap Growth Fund
$1.0M position · as of 2026-07-31
1.3%
Direxion Daily Retail Bull 3X Shares
$334.7K position · as of 2026-07-31
1.2%
Emerald Growth Fund
$17.5M position · as of 2026-07-31
1.2%
Small-Company Stock Fund
$2.3M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · L. Reade Fahs
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$8.6M
$6.9M
$2.0M
-37%
+52%
2022
$4.3M
$757.2K
$1.1M
+17%
+11%
2021
$5.7M
$7.9M
$1.5M
+45%
+64%
2020
$4.0M
$6.5M
$1.0M
+37%
+39%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $776.0K bought by insiders over 180 days, 131 funds added last quarter. Each figure is a federal filing, dated the day it went public.
EYE financials
Revenue growth
+9.0%
XBRL, annual
Net margin
1.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.0B
four quarters, 2025-06-29 to 2026-07-04
Revenue, TTM EYE
| FY Jan 2026 | $2.0B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $2.0B |
| FY Jan 2022 | $2.1B |
| Jul 2026 | $498.8M |
| Apr 2026 | $543.9M |
| Jan 2026 | $503.4M |
| Sep 2025 | $487.3M |
| Jun 2025 | $486.4M |
| Mar 2025 | $510.3M |
| Dec 2024 | $437.3M |
| Sep 2024 | $451.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+2.5%
net income over revenue, 2025-06-29 to 2026-07-04
Net margin, TTM EYE
| FY Jan 2026 | +1.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +2.1% |
| FY Jan 2022 | +6.2% |
| Jul 2026 | +2.5% |
| Apr 2026 | +5.7% |
| Jan 2026 | +0.7% |
| Sep 2025 | +0.7% |
| Jun 2025 | +1.8% |
| Mar 2025 | +2.8% |
| Dec 2024 | -6.5% |
| Sep 2024 | -1.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$49.1M
operating cash flow minus capex, 2025-06-29 to 2026-07-04
Free cash flow, TTM EYE
| FY Jan 2026 | $73.5M |
| FY Dec 2024 | $38.1M |
| FY Dec 2023 | $58.3M |
| FY Dec 2022 | $5.7M |
| FY Jan 2022 | $163.4M |
| Jul 2026 | -$14.1M |
| Apr 2026 | $44.1M |
| Jan 2026 | -$11.2M |
| Sep 2025 | $30.3M |
| Jun 2025 | $42.4M |
| Mar 2025 | $12.0M |
| Dec 2024 | -$1.7M |
| Sep 2024 | $4.1M |
At each fiscal year end
Single quarter
Debt to equity
0.26x
long-term 2026-07-04 plus current 2026-07-04; equity 2026-07-04
Debt to equity EYE
| FY Jan 2026 | 0.27x |
| FY Dec 2024 | 0.41x |
| FY Dec 2023 | 0.54x |
| FY Dec 2022 | 0.61x |
| FY Jan 2022 | 0.59x |
| Jul 2026 | 0.26x |
| Apr 2026 | 0.26x |
| Jan 2026 | 0.27x |
| Sep 2025 | 0.28x |
| Jun 2025 | 0.31x |
| Mar 2025 | 0.40x |
| Dec 2024 | 0.41x |
| Sep 2024 | 0.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.56x
TTM operating cash flow over long-term 2026-07-04 plus current 2026-07-04
Cash flow to debt EYE
| FY Jan 2026 | 0.62x |
| FY Dec 2024 | 0.40x |
| FY Dec 2023 | 0.39x |
| FY Dec 2022 | 0.22x |
| FY Jan 2022 | 0.48x |
| Jul 2026 | 0.56x |
| Apr 2026 | 0.75x |
| Jan 2026 | 0.62x |
| Sep 2025 | 0.67x |
| Jun 2025 | 0.55x |
| Mar 2025 | 0.42x |
| Dec 2024 | 0.40x |
| Sep 2024 | 0.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+5.8%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on equity EYE
| FY Jan 2026 | +3.5% |
| FY Dec 2024 | -3.5% |
| FY Dec 2023 | -7.6% |
| FY Dec 2022 | +4.6% |
| FY Jan 2022 | +14.0% |
| Jul 2026 | +5.8% |
| Apr 2026 | +5.4% |
| Jan 2026 | +3.5% |
| Sep 2025 | -0.3% |
| Jun 2025 | -1.7% |
| Mar 2025 | -3.1% |
| Dec 2024 | -3.5% |
| Sep 2024 | -1.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.5%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on assets EYE
| FY Jan 2026 | +1.5% |
| FY Dec 2024 | -1.4% |
| FY Dec 2023 | -3.0% |
| FY Dec 2022 | +1.8% |
| FY Jan 2022 | +5.5% |
| Jul 2026 | +2.5% |
| Apr 2026 | +2.3% |
| Jan 2026 | +1.5% |
| Sep 2025 | -0.1% |
| Jun 2025 | -0.7% |
| Mar 2025 | -1.2% |
| Dec 2024 | -1.4% |
| Sep 2024 | -0.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.7%
operating income after a 26.3% effective tax rate, over long-term 2026-07-04 plus current 2026-07-04 plus average of 2025-06-28 and 2026-07-04 minus cash
Return on invested capital EYE
| FY Jan 2026 | +4.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +3.1% |
| FY Jan 2022 | +13.4% |
| Jul 2026 | +5.7% |
| Apr 2026 | +5.7% |
| Jan 2026 | +4.1% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.3%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-07-04 minus current liabilities
Return on capital employed EYE
| FY Jan 2026 | +3.8% |
| FY Dec 2024 | -0.6% |
| FY Dec 2023 | +1.3% |
| FY Dec 2022 | +2.7% |
| FY Jan 2022 | +8.8% |
| Jul 2026 | +5.3% |
| Apr 2026 | +5.0% |
| Jan 2026 | +3.8% |
| Sep 2025 | +1.7% |
| Jun 2025 | +0.5% |
| Mar 2025 | -0.5% |
| Dec 2024 | -0.6% |
| Sep 2024 | +0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
30.61x
close 2026-10-23 over four quarters of diluted EPS, 2025-06-29 to 2026-07-04
P/E, trailing EYE
| FY Jan 2026 | 70.14x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 77.52x |
| FY Jan 2022 | 33.33x |
| Jul 2026 | 32.39x |
| Apr 2026 | 41.56x |
| Jan 2026 | 70.14x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.7B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-07-04 plus current 2026-07-04, minus cash 2026-07-04
Enterprise value EYE
| FY Jan 2026 | $2.3B |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $3.4B |
| FY Jan 2022 | $4.2B |
| Jul 2026 | $1.8B |
| Apr 2026 | $2.0B |
| Jan 2026 | $2.3B |
| Sep 2025 | $2.4B |
| Jun 2025 | $2.0B |
| Mar 2025 | $1.3B |
| Dec 2024 | $1.1B |
| Sep 2024 | $1.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield EYE
| FY Jan 2026 | +3.6% |
| FY Dec 2024 | +4.6% |
| FY Dec 2023 | +3.6% |
| FY Dec 2022 | +0.2% |
| FY Jan 2022 | +4.1% |
| Jul 2026 | +3.1% |
| Apr 2026 | +5.6% |
| Jan 2026 | +3.6% |
| Sep 2025 | +3.7% |
| Jun 2025 | +3.1% |
| Mar 2025 | +4.6% |
| Dec 2024 | +4.6% |
| Sep 2024 | +3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing EYE
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | 0.14x |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-01 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.0B | $1.8B | $2.1B | $2.0B |
| Operating income | $58.8M | -$10.4M | $24.5M | $52.8M |
| Net income | $29.6M | -$28.5M | -$65.9M | $42.1M |
| EPS (diluted) | 0.37 | -0.36 | -0.84 | 0.52 |
| Operating cash flow | $146.3M | $133.6M | $173.0M | $119.2M |
| Cash | $38.7M | $73.9M | $149.9M | $229.4M |
| Long-term debt | $223.2M | $239.1M | $437.7M | $546.2M |
| Buybacks | $3.2M | $3.1M | $28.4M | $84.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
EYE Stock Sonar score 6/7 axes
Find similar shapesCompareEYE ranks highest on insider conviction (71st percentile) and institutional and government (71st), and lowest on risk and compliance (49th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EYE filings, in plain words
Are National Vision insiders buying or selling EYE?
In the 180 days to 2026-10-28, National Vision insiders were net buyers, a net $776.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, National Vision insiders were net buyers of EYE, a net $776.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
